Eikon Therapeutics vs insitro (2026)
Two companies that both refuse to learn from data somebody else collected, and they built different instruments to avoid it. Eikon watches proteins move inside living cells using super resolution microscopy descended from Nobel recognised single molecule imaging, which produces a kind of dynamic measurement nobody else in this category has. insitro generates its own multimodal cellular data through stem cell models, genome editing and high content imaging, with its core method in peer review and experimental testing built into the loop. Eikon is further along at the asset level with disclosed clinical work and public reporting behind it. Both describe the measurement beautifully and the computational layer barely at all, which is the question to put to either: what exactly do the models do with all that imaging.
- The differentiating asset is an instrument rather than a model, applying super resolution live cell microscopy descended from Nobel recognised work to watch individual proteins move inside living cells.
- Regulatory activity is real at the asset level, with disclosed clinical work in oncology, and the company has entered public reporting so its capital position is documented.
- The platform screens and characterises targets to feed medicinal chemistry decisions rather than claiming to replace them, which is an honest account of what it does.
- It generates its own multimodal cellular data through stem cell models, genome editing and high content imaging, so the platform produces the biology it learns from.
- The core method was submitted to peer review rather than described in marketing, which is the standard this index rewards.
- Model hypotheses are tested experimentally before they advance, which puts the wet laboratory inside the loop rather than downstream of it.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Eikon Therapeutics and insitro are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Eikon Therapeutics | insitro |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2019 | 2018 |
| Headquarters | South San Francisco, CA | South San Francisco, CA |
| Website | eikontx.com | insitro.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index records no top capability grade for Eikon Therapeutics on any axis it scores. Set against insitro, Eikon Therapeutics grades higher on FDA and Regulatory Status. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards insitro its top capability grade on AI Centrality and Model and Technology Transparency. Set against Eikon Therapeutics, insitro grades higher on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Eikon Therapeutics or insitro?
On the axes where the AI Health Index separates them, Eikon Therapeutics grades higher on FDA and Regulatory Status, and insitro grades higher on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. insitro leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Eikon Therapeutics and insitro differ most?
The widest separation the AI Health Index records between Eikon Therapeutics and insitro is on Model and Technology Transparency, where Eikon Therapeutics grades C and insitro grades A. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Eikon Therapeutics and insitro grade the same?
The AI Health Index grades Eikon Therapeutics and insitro the same on several axes, including Autonomy and Oversight Model, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Eikon Therapeutics and insitro not disclosed?
At the last review, at least one of Eikon Therapeutics and insitro published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both companies describe their measurement approach clearly and their computational layer barely at all, which is the shared gap and the thing a partner should press: what the models actually do with the imaging data is undocumented on both sides. Neither publishes cohort or cell line provenance, which is where the bias question lives for platforms learning from their own biology.
Neither holds a located security attestation, and both are correctly assessed as discovery organisations rather than against provider oriented axes, so those grades are scoping determinations rather than absences.